Emcure Pharmaceuticals Ltd. (Emcure) and Sanofi India Limited (SIL) have announced an exclusive distribution and promotion partnership for Sanofi’s oral anti-diabetic (OAD) products in India, with immediate effect.
As part of the agreement, Emcure will distribute and promote Sanofi’s OAD brands, including the well-established Amaryl® and Cetapin®. While Sanofi will retain ownership and manufacturing responsibilities across its facilities in India and globally, Emcure will utilize its extensive reach to connect with healthcare professionals and expand patient access across India. Notably, there will be no employee transition from SIL to Emcure under this arrangement.
Eric Mansion, General Manager Pharma Southeast Asia and India & MCO Lead, Sanofi, said: “Over 100 million Indians are living with type 2 diabetes and its complexities in India. Of these, >60% people are living with uncontrolled blood sugar levels and have a higher risk of developing complications, over a long period of time. Sanofi’s commitment to improving their lives and helping them manage their diabetes better remains unwavering. With Emcure’s wide and deeply penetrated presence across India, we’re confident of tapping into the full growth potential of our best-in-class & industry-leading OADs Amaryl® and Cetapin®. This partnership will truly benefit both – the patients who need them and the HCPs who trust and prescribe them.”
Satish Mehta, CEO and MD, Emcure Pharmaceuticals Ltd., added: “At Emcure, we are committed to improving patient access to high-quality therapies. With our strong distribution network in India, Sanofi’s trusted oral anti-diabetic medicines will be available to more patients who need them. This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country.”
